Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia

Cancer Science

Volumn 99, Issue 5, 2008, Pages 1016-1020

  Yamaguchi, Motoko ^a   Suzuki, Ritsuro ^b   Kwong, Yok Lam ^c   Kim, Won Seog ^d   Hasegawa, Yuichi ^e   Izutsu, Koji ^f   Suzumiya, Junji ^g   Okamura, Takayuki ^h   Nakamura, Shigeo ⁱ   Kawa, Keisei ^j   Oshimi, Kazuo ^k  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f Kanto Teishin Hospital   (Japan)

^g Fukuoka University Chikushi Hospital   (Japan)

^h UNIVERSITY OF THE RYUKYUS   (Japan)

ⁱ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^k JUNTENDO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; PREDNISOLONE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; ERYTHROCYTE TRANSFUSION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOFIBRINOGENEMIA; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; STOMATITIS; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; EXTRANODAL LYMPHOMA; LYMPHATIC LEUKEMIA; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; DEXAMETHASONE; ETOPOSIDE; HUMANS; IFOSFAMIDE; LEUKEMIA, LYMPHOID; LYMPHOMA, EXTRANODAL NK-T-CELL; METHOTREXATE; MIDDLE AGED; RECURRENCE;

EID: 43649085643     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00768.x     Document Type: Article

References (33)

1. Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematop 2005; 45: 51-70.
2. Oshimi K. Progress in understanding and managing NK-cell malignancies. Br J Haematol 2007; 139: 532-44.
3. Jaffe ES, Chan JK, Su IJ et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103-11.
4. Suzuki R, Suzumiya J, Nakamura S et al. Aggressive natural killer-cell leukemia revisited: Large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763-70.
5. Yamaguchi M, Kita K, Miwa H et al. Frequent expression of P-glycoprotein/ MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 2351-6.
6. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999; 93: 599-606.
7. Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004; 103: 216-21.
8. Oshimi K, Kawa K, Nakamura S et al. NK-cell neoplasms in Japan. Hematology 2005; 10: 237-45.
9. Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-18.
10. Yamaguchi M, Ogawa S, Nomoto Y et al. Treatment outcome of nasal NK-cell lymphoma: A report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematop 2001; 41: 93-9.
11. Ribrag V, Ell Hajj M, Janot F et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001; 15: 1123-6.
12. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: Clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182-90.
13. Koom WS, Chung EJ, Yang WI et al. Angiocentric T-cell and NK/T-cell lymphomas: Radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004; 59: 1127-37.
14. Yamaguchi M, Oguchi M, Tobinai K et al. Phase I/II study of concurrent chemoradiotherapy for newly-diagnosed, localized nasal NK/T-cell lymphoma: Results of a phase I portion of JCOG0211-DI. ASH Annu Meeting Abstracts 2005; 106: 2685.
15. Murashige N, Kami M, Kishi Y et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 561-7.
16. Suzuki R, Suzumiya J, Nakamura S et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006; 37: 425-31.
17. Uno M, Tsuchiyama J, Moriwaki A et al. In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol 2001; 113: 1009-14.
18. Lee KW, Yun T, Kim DW et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/-radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 2006; 47: 1274-82.
19. Imashuku S, Kuriyama K, Teramura T et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19: 2665-73.
20. Kawa K. Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease. Int J Hematol 2003; 78: 24-31.
21. Ando M, Sugimoto K, Kitoh T et al. Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol 2005; 130: 860-8.
22. Nagafuji K, Fujisaki T, Arima F, Ohshima K. l-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 447-50.
23. Yong W, Zheng W, Zhang Y et al. L-Asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003; 78: 163-7.
24. Nowak-Gottl U, Ahlke E, Fleischhack G et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): Prednisone versus dexamethasone administration. Blood 2003; 101: 2529-33.
25. Aviles A, Neri N, Fernandez R, Calva A, Huerta-Guzman J, Nambo MJ. Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 2003; 20: 13-17.
26. Yazawa Y, Takagi T, Asakura S, Suzuki K, Kano Y. Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines. J Orthop Sci 1999; 4: 231-7.
27. Lorico A, Boiocchi M, Rappa G, Sen S, Erba E, D'Incalci M. Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate. Int J Cancer 1990; 45: 156-62.
28. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
29. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979.
30. Kwong YL. Natural killer-cell malignancies: Diagnosis and treatment. Leukemia 2005; 19: 2186-94.
31. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-53.
32. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
33. Kako S, Izutsu K, Ota Y et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007; 18: 1685-90.